The CMP™ platform enables expression of full-length, multi-pass membrane proteins with preserved structure and function. Using a virus-like particle (VLP) format, these nanoparticles display higher density target membrane proteins with a native conformation and are expressed in mammalian cells to preserve the natural post-translational process. The viral capsid backbone is engineered to increase VLP release for higher production yield.
These proteins are ideal for functional studies, antibody discovery, and drug screening.
Combining multiple proprietary protein engineering techniques for:
Membrane proteins embedded within lipid bilayer-based cell plasma membranes make up large portions of human proteome
Receptors, transporters, ion channels and enzymes related to cell membranes mediate interactions between cells and their environment
More than 60% of the current drugs target membrane proteins
Membrane proteins are not typically abundant on the cell surface making them very difficult to purify and characterize
Membrane proteins are structurally complex, taking on various conformational forms
Single transmembrane domain
4-transmembrane domains
7-transmembrane domains
Categories of complex membrane proteins can be expressed using the CMP technology platform: GPCRs, Claudin family, ion channels, and immuno-oncology targets
Membrane proteins are central to drug targeting and immune recognition, yet difficult to express in functional form. Many methods, including detergent solubilization or peptide synthesis distort structural integrity and epitope presentation.
The CMP™ technology platform resolves these challenges by preserving native folding and membrane context. This supports:
Example Membrane Protein Nanoparticle: CXCR4 (7-transmembrane domain GPCR)
The cell surface C-X-C chemokine receptor 4 (CXCR4) is a seven transmembrane domain G protein-coupled receptor (GPCR), expressed on white blood cells and hematopoetic stem cells. CXCL12 is the endogenous chemokine ligand of CXCR4, and the CXCL12/CXCR4 complex activates various signaling pathways promoting chemotaxis, adhesion and migration, cell proliferation and survival. This receptor also acts with the CD4 protein as a co-receptor to mediate HIV entry into cells.
Human CXCR4 protein CMP (CMP-24005) potently binds to CXCR4 specific monoclonal antibody (mAb) as measured by ELISA. The CXCR4 protein (0.5 μg/ml) was coated on 96-well microtiter plates and detected by serial dilutions of anti-human CXCR4 mAb.
Human CXCR4 protein CMP (CMP-24005) binds well to its ligand CXCL12 chemokine as measured by ELISA. The CXCL12 protein (0.5 μg/ml) was coated on 96-well microtiter plates and detected by serial dilutions of CXCR4-CMP.
Human CXCR4 protein CMP (CMP-24005) binds well to its ligand HIV-1 envelope glycoprotein gp120 as measured by ELISA. The gp120 protein (0.5 μg/ml) was coated on 96-well microtiter plates and detected by serial dilutions of CXCR4-CMP.
The nanoparticle stability is comparable to the stability of other purified proteins. Nanoparticles are stable for at least 6 month when frozen (-70°C) or at least 14 days at 4°C. Like most lipid structures, nanoparticles will be disrupted by detergents. Nanoparticle suspensions will appear as an opaque solution and should be gently mixed before use. Excessive vortexing, dilution, and filtration of nanoparticles should be avoided to minimize sample loss. More information can be found on the datasheet.
The nanoparticles can readily be modified during the production and purification process. Please contact Conigen to request biotinylated or fluorescently labeled molecules.
As nanoparticles bud from the cell surface, they contain high-copy numbers of specific target membrane protein of interest in addition to membrane proteins from the cells that are used for production. The effects of these nonspecific membrane proteins are minimized by the overexpression of the target membrane protein of interest. In your experimental set-up, Conigen recommends the following negative controls: alternative cell types, and the use of null nanoparticles that do not contain the target membrane protein of interest.
Generally, nanoparticles range in size (diameter) from approximately 100 to 300nm.
The Conigen validation process involves various analytical techniques for each batch, including techniques such as dynamic light scatter, Western blot, and ELISA
Please contact Conigen at [email protected] to place an order via PO.
Please contact Conigen using the Consultation request form.
The turnaround time of custom orders is approximately 6-8 weeks from sequence to product. Please contact Conigen using the Consultation request form for more information.
Poster Abstract Antibody staining of G protein-coupled receptors (GPCRs) on live cells is important for studying receptor expression, localization, and dynamics in their native, functional
Poster Abstract CXCR4 and CXCR5 are G-protein coupled receptors (GPCRs). CXCR4 is a receptor for chemokine CXCL12 and a co-receptor for HIV to infect CD4
Conigen Bioscience is Exhibiting at Discovery on Target Poster Presentations Recombinant Bioactive CXCR4 or CXCR5 on Virus-Like Nanoparticles Can Bind to Their Chemokine Ligand CXCL12
Overview Understanding cytokine-receptor interactions is critical for advancing immunology research and therapeutic development, but capturing these interactions in a native-like state can be challenging. In
DivcoWest and BVS’ Biotech Summer BBQ Event at Cambridge Crossing Date: Wednesday, July 30, 2025Event Time: 11:00 AM – 1:30 PMLocation: 222 Jacobs St, Cambridge,
Live Webinar: Uncovering New Tools to Analyze Cytokine-Receptor Interactions How Conigen Bioscience Used Nicoya’s AltoTM DIgital SPR to Characterize Novel Dimeric Receptors Register Now Tuesday,
